Legal & General Group
IMRX icon

Legal & General Group’s Immuneering IMRX Stock Holding History

Legal & General Group’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,168
Closed -$6.27K – 3464
2024
Q1 		$6.27K Hold
2,168
– – ﹤0.01% 3271
2023
Q4 		$16K Sell
2,168
-476
-18% -$3.17K ﹤0.01% 3116
2023
Q3 		$20.3K Buy
2,644
+302
+13% +$2.78K ﹤0.01% 3021
2023
Q2 		$23.7K Buy
+2,342
New +$22.5K ﹤0.01% 3036
2022
Q3 		– Sell
-1,591
Closed -$9K – 3469
2022
Q2 		$9K Sell
1,591
-271
-15% -$1.45K ﹤0.01% 3382
2022
Q1 		$12K Buy
1,862
+1,088
+141% +$10.4K ﹤0.01% 3364
2021
Q4 		$13K Hold
774
– – ﹤0.01% 3402
2021
Q3 		$20K Buy
+774
New +$20.8K ﹤0.01% 3271

Other funds holding IMRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Legal & General Group's IMRX Position: Q2 2024 in Review

Legal & General Group sold out of Immuneering (IMRX) in Q2 2024, closing a stake of 2,168 shares — an estimated $6.27K sold.

Legal & General Group first reported a position in IMRX in Q3 2021 and held it in 8 quarters. The position peaked at $23.7K in Q2 2023. 59 funds tracked by Wall St. Rank hold IMRX as of Q2 2024.

  • Legal & General Group reported no remaining Immuneering position as of Q2 2024 after selling out during the quarter.
  • Legal & General Group sold 2,168 Immuneering shares in Q2 2024, an estimated $6.27K.
  • Legal & General Group first reported a position in Immuneering in Q3 2021 and held it in 8 quarters.
  • Legal & General Group's Immuneering position peaked at $23.7K in Q2 2023.
  • 59 funds tracked by Wall St. Rank held Immuneering as of Q2 2024.

Based on Legal & General Group's 13F filing for Q2 2024, filed 14 Aug 2024.